Evaluation of p16/Ki-67 dual stain cytology performed on self-collected vaginal and clinician-collected cervical specimens for the detection of cervical pre-cancer.
To compare the performance of dual immunostaining of p16INK4a and Ki-67 proteins performed on self-collected vaginal specimens and clinician-collected cervical specimens, as well as its performance in predicting high-grade disease. Women aged 30-59 years (N=1005) were recruited at two well-women clinics in Papua New Guinea. Each woman provided both a cervical and vaginal specimen that were tested for hrHPV DNA using the Xpert HPV Test (Cepheid) at point-of-care. A subset of paired cervical and vaginal specimens (n=243) were selected to undergo CINTec® PLUS (Roche) p16/Ki-67 dual stain cytology and liquid-based cytology (LBC). Fifty-five (22%) pairs were excluded from further analysis because smears were not assessable. Of the 189 remaining paired specimens, 74 (39.1%) pairs were positive for one or more hrHPV genotype. When comparing dual stain results, the overall percent agreement, positive and negative percent agreements and kappa value between the cervical and vaginal specimens were 87.8% (CI 82.3-92.1%), 64.6% (CI 49.5-77.8%), 95.7% (CI 91.0-98.0%) and 0.65 (CI 0.51-0.79%) respectively. The sensitivity of dual stain performed on the cervical specimen to predict high-grade disease, determined by LBC, was superior to that of dual stain performed on the vaginal specimen; 100% (CI 84.6-100%) versus 68.2% (CI 45.1-86.1%). Although further evaluation may be warranted, these findings indicate that dual stain testing of vaginal specimens cannot be advocated as part of cervical screening programs in low and middle-income countries. Dual stain cytology performed on cervical specimens may however have a role in quality assurance in such settings.